Industry
Research and Development in Biotechnology (except Nanobiotechnology)
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
Loading...
Open
0.06
Mkt cap
119K
Volume
20K
High
0.06
P/E Ratio
0.01
52-wk high
14.75
Low
0.03
Div yield
N/A
52-wk low
0.00
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.